Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the
tumor smaller and reduce the amount of normal tissue that needs to be removed.
PURPOSE: This phase II trial is studying how well pazopanib hydrochloride works when given
before surgery in treating patients with kidney cancer.